Overview of the RFX Fusion Science Program

With a program well-balanced among the goal of exploring the fusion potential of the reversed field pinch (RFP) and that of contributing to the solution of key science and technology prob- lems in the roadmap to ITER, the European RFX-mod device has produced a set of high-quality results since the last 2010 Fusion Energy Conference. RFX-mod is a 2 MA RFP, which can also be operated as a tokamak and where advanced confinement states have 3D features studied with stellarator tools. Self-organized equilibria with a single helical axis and improved confinement (SHAx) have been deeply investigated and a more profound understanding of their physics has been achieved. First wall conditioning with Lithium provides a tool to operate RFX at higher density than before, and application of helical magnetic boundary conditions favour stationary SHAx states. The correlation between the quality of helical states and the reduction of magnetic field errors acting as seed of magnetic chaos has been robustly proven. Helical states provide a unique test-bed for numerical codes conceived to deal with 3D effects in all magnetic configura- tions. In particular the stellarator equilibrium codes VMEC and V3FIT have been successfully adapted to reconstruct RFX-mod equilibria with diagnostic input. The border of knowledge has been significantly expanded also in the area of feedback control of MHD stability. Non-linear dynamics of tearing modes and their control has been modelled, allowing for optimization of feedback models. An integrated dynamic model of the RWM control system has been developed integrating the plasma response to multiple RWMs with active and passive conducting structures (CarMa model) and with a complete representation of the control system. RFX has been oper- ated as a tokamak with safety factor kept below 2, with complete active stabilization of the p2, 1q Resistive Wall Mode (RWM). This opens the exploration of a broad and interesting operational range otherwise excluded to standard tokamaks. Control experiments and modelling led to the design of a significant upgrade of the RFX-mod feedback control system to dramatically enhance computing power and reduce system latency. The possibility of producing D-shaped plasmas is being explore

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

Abstract Background BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). Methods We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database. Results Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10−5) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor–positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15–21.80] and progesterone receptor–positive (OR 5.04; 95 % CI 3.17–8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10−12). Conclusions On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

Abstract Background BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). Methods We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database. Results Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10−5) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor–positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15–21.80] and progesterone receptor–positive (OR 5.04; 95 % CI 3.17–8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10−12). Conclusions On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management